The impact of macular pigment augmentation on visual performance using different carotenoid formulations

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 12, 2012, Pages 7871-7880

  Loughman, James ^a,b   Nolan, John M ^c,d   Howard, Alan N ^e   Connolly, Eithne ^c,d   Meagher, Katie ^c   Beatty, Stephen ^c,d  

^a DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^b University of KwaZulu Natal Faculty of Health Sciences   (South Africa)

^c Ireland   (Ireland)

^d Institute of Vision Research   (Ireland)

^e DOWNING COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; XANTHOPHYLL; ZEAXANTHIN; ANTIOXIDANT; CAROTENOID;

ADULT; AGED; ARTICLE; CONTRAST SENSITIVITY; CONTROLLED STUDY; FEMALE; GLARE; HUMAN; LIGHT STRESS; MALE; OPTICAL DENSITY; PHOTOMETRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA LUTEA; VISION; VISUAL ACUITY; ADOLESCENT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; PROSPECTIVE STUDY; RETINA MACULA DEGENERATION; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIOXIDANTS; CAROTENOIDS; DIETARY SUPPLEMENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACULA LUTEA; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL PIGMENT EPITHELIUM; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 84872201091     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10690     Document Type: Article

References (46)

1. Snodderly DM, Auran JD, Delori FC. The macular pigment 2. Spatial-distribution in primate retinas. Invest Ophthalmol Vis Sci. 1984;25:674-685.
2. Khachik F, Bernstein PS, Garland DL. Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci. 1997;38:1802-1811.
3. Reading VM, Weale RA. Macular pigment and chromatic aberration. J Opt Soc Am. 1974;64:231-234.
4. Stringham JM, Hammond BR Jr. The glare hypothesis of macular pigment function. Optom Vis Sci. 2007;84:859-864.
5. Wooten BR, Hammond BR. Macular pigment: influences on visual acuity and visibility. Prog Ret Eye Res. 2002;21:225-240.
6. Hemenger RP. Dichroism of the macular pigment and Haidinger's brushes. J Opt Soc Am. 1982;72:734-737.
7. Kvansakul J, Rodriguez-Carmona M, Edgar DF. Supplementation with the carotenoids lutein or zeaxanthin improves human visual performance. Ophthal Physiol Opt. 2006;26: 362-371.
8. Stringham JM, Garcia PV, Smith PA, McLin LN, Foutch BK. Macular pigment and visual performance in glare: benefits for photostress recovery, disability glare, and visual discomfort. Invest Ophthalmol Vis Sci. 2011;52;7406-7415.
9. Weigert G, Kaya S, Pemp B, et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:8174-8178.
10. Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004;75;216-230.
11. Li B, Ahmed F, Bernstein PS. Studies on the singlet oxygen scavenging mechanism of human macular pigment. Arch. Biochem. Biophys. 2010;504:56-60.
12. Bone RA, Landrum JT, Friedes LM, et al. Distribution of lutein and zeaxanthin stereoisomers in the human retina. Exp Eye Res. 1997;64:211-218.
13. Okulski W, Sujak A, Gruszecki WI. Dipalmitoylphosphatidyl-choline membranes modified with zeaxanthin: numeric study of membrane organisation. Biochim Biophys Acta. 2000;1509: 216-228.
14. Connolly E, Beatty S, Thurnham DI, et al. Augmentation of macular pigment following supplementation with all three macular carotenoids: an exploratory study. Curr Eye Res. 2010;35;335-351.
15. Kirby ML, Beatty S, Loane E, et al. A central dip in the macular pigment spatial profile is associated with age and smoking. Invest Ophthalmol Vis Sci. 2010;51:6722-6728.
16. Stringham JM, Hammond BR, Nolan JM, et al. The utility of using customized heterochromatic flicker photometry (cHFP) to measure macular pigment in patients with age-related macular degeneration. Exp Eye Res. 2008;87:445-453.
17. Loughman J, Beatty S, Akkalli M, et al. The relationship between macular pigment and visual performance. Vis Res. 2010;50:1249-1256.
18. Nolan JM, Loughman J, Akkali MC, et al. The impact of macular pigment augmentation on visual performance in normal subjects: COMPASS. Vis Res. 2011;51:459-469.
19. Dhalla MS, Fantin A, Blinder KJ, Bakal JA. The macular automated photostress test. Am J Ophthalmol. 2007;143;596-600.
20. Dhalla MS, Fantin A. Macular photostress testing: sensitivity and recovery with an automated perimeter. Retina. 2005;25: 189-192.
21. Seddon JM, Sahagian CR, Glynn RJ, et al. Evaluation of an iris classification system. Invest Ophthalmol Vis Sci. 1990;31: 1592-1598.
22. Connolly EE, Beatty S, Loughman J, Howard AN, Louw MS, Nolan JM. Supplementation with all three macular caroten-oids: response, stability, and safety. Invest Ophthalmol Vis Sci. 2011;52:9207-9217.
23. Nolan JM, Akkali MC, Loughman J, Howard AN, Beatty S. Macular carotenoid supplementation in subjects with a "central dip or plateau" in their macular pigment spatial profile. Exp Eye Res. 2012;101:9-15.
24. Liew M, Gilbert CE, Spector T, et al. The heritability of macular pigment: a twin study. Invest Ophthalmol Vis Sci. 2005;46: 4430-4436.
25. Bone RA, Landrum JT, Guerra LH, Ruiz CA. Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr. 2003;133:992-998.
26. Trieschmann M, Beatty S, Nolan JM, et al. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res. 2007;84:718-728.
27. Johnson EJ, Hammond BR, Kyung-Jin Y, et al. Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. Am J Clin Nutr. 2000;71;1555-1562.
28. Bone RA, Landrum JT, Fernandez L, Tarsis SL. Analysis of the macular pigment by HPLC: retinal distribution and age study. Invest Ophthalmol Vis Sci. 1988;29:843-849.
29. Johnson EJ, Neuringer M, Russell RM, Schalch W, Snodderly DM. Nutritional manipulation of primate retinas, III: effects of lutein or zeaxanthin supplementation on adipose tissue and retina of xanthophyll-free monkeys. Invest Ophthalmol Vis Sci. 2005;46:692-702.
30. Bone RA, Landrum JT, Hime GW, Cains A, Zamor J. Stereochemistry of the human macular carotenoids. Invest Ophthalmol Vis Sci. 1993;34:2033-2040.
31. Loughman J, Davison P, Akkalli M, Nolan J, Beatty S. Visual performance and macular pigment. J Optom. 2010;3:73-89.
32. Stringham JM, Fuld K, Wenzel AJ. Action spectrum for photophobia. J Opt Soc Am. 2003;20:1852-1858.
33. Stringham JM, Fuld K, Wenzel AJ. Spatial properties of photophobia. Invest Ophthalmol Vis Sci. 2004;45:3838-3848.
34. Wenzel AJ, Fuld K, Stringham JM, Curran-Celantano J. Macular pigment optical density and photophobia light threshold. Vis Res. 2006;46:4615-4622.
35. Engles M, Wooten B, Hammond BR. Macular pigment: a test of the acuity hypothesis. Invest Ophthalmol Vis Sci. 2007;48: 2922-2931.
36. Hammond BR, Wooten BR. CFF thresholds: relation to macular pigment optical density. Ophthalmic Physiol Opt. 2005;25: 315-319.
37. Renzi LM, Hammond BR. The relationship between macular carotenoids, lutein and zeaxanthin, and temporal vision. Ophthalmic Physiol Opt. 2010;30:351-357.
38. Ratliff F, Hartline HK, Miller WH. Spatial and temporal aspects of retinal inhibitory interaction. J Opt Soc Am. 1963;53:110-120.
39. Powell RR. Flicker fusion as a typological index of nervous system reactivity. Percept Mot Skills. 1983;57:701-702.
40. Johnson EJ, McDonald K, Calderella SM, Chung HY, Troen AM, Snodderly DM. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr Neurosci. 2008;11:75-83.
41. Vishwanathan R, Neuringer M, Snodderly DM, Schalch W, Johnson EJ. Macular lutein and zeaxanthin are related to brain lutein and zeaxanthin in primates [published online ahead of print July 9, 2012]. Nutr Neurosci. doi:10.1179/ 1476830512Y.
42. Dagnelie G, Zorge IS, McDonald TM. Lutein improves visual function in some patients with retinal degeneration: a pilot study via the Internet. Optometry. 2000;71:147-164.
43. Hammond BR, Wooten B, Snodderly DM. Preservation of visual sensitivity of older subjects: association with macular pigment density. Invest Ophthalmol Vis Sci. 1998;39:397-406.
44. Sabour Pickett S, Nolan JM, Loughman J, Beatty S. A review of the evidence germane to the putative protective role of the macular carotenoids for age-related macular degeneration. Mol Nutr Food Res. 2012;56:270-286.
45. Craft NE, Haitema TB, Garnett KM, Fitch KA, Dorey CK. Carotenoid, tocopherol, and retinol concentrations in elderly human brain. J Nutr Health Aging. 2004;8:156-162.
46. Chang CJG. Thirteen week oral (gavage) toxicity of meso-zeaxanthin in Han Wister rats with a 4-week recovery. Study no. 1567-04370. Gaithersburg, MD: Gene Logic Laboratories, Inc., 2006.